Denali Therapeutics (DNLI) Operating Income (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Operating Income data on file, last reported at -$137.4 million in Q1 2026.

• On a quarterly basis, Operating Income rose 5.65% year-over-year to -$137.4 million in Q1 2026; TTM through Mar 2026 was -$547.1 million, a 6.19% decrease from a year earlier, with the FY2025 full-year figure at -$555.3 million, down 13.95% from the prior year.
• Operating Income for Q1 2026 stood at -$137.4 million, roughly flat from -$137.4 million in the prior quarter.
• Over the last five years, Operating Income for DNLI reached as high as $170.5 million in Q2 2023 and fell as low as -$145.6 million in Q1 2025.
• Historically, Operating Income has averaged -$101.0 million across 5 years, with a median of -$120.8 million in 2023.
• Across the five-year window, Operating Income surged 377.59% in 2023 and plunged 168.39% in 2024, its largest moves.
• Year by year, Operating Income stood at -$105.3 million in 2022, then dropped by 25.85% to -$132.6 million in 2023, then rose by 2.06% to -$129.8 million in 2024, then decreased by 5.79% to -$137.4 million in 2025, then increased by 0.01% to -$137.4 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$137.4 million in Q1 2026, -$137.4 million in Q4 2025, and -$137.4 million in Q3 2025.